home / stock / anvs / anvs articles
BERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies ...
BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies ...
Michael Hoffman, Board Member at Annovis Bio (NYSE:ANVS), reported a large insider buy on November 22, according to a new SEC filing. What Happene...
Annovis Bio Inc (NYSE: ANVS) shares are trading lower by 17.9% to $6.69 Tuesday morning after the company announced a public offering of 1.25 ...
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 38.8% to $0.1250 in pre-market trading. LumiraDX shares fell 25% on Monday after the company ...
News, Short Squeeze, Breakout and More Instantly...
The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson’s Disease patients Following the announcement of these positive results, the company’s stock price surged by 76% The data revealed that while 12%...
Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023 The company’s research focuses on inhibiting the production of ...
Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food an...